<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547350</url>
  </required_header>
  <id_info>
    <org_study_id>PIC-UTUC</org_study_id>
    <nct_id>NCT02547350</nct_id>
  </id_info>
  <brief_title>Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuesong Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of prophylactic intravesical
      chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder
      recurrence after nephroureterectomy for upper tract urothelial carcinoma (UTUC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intravesical recurrence-free survival</measure>
    <time_frame>two years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cancer-specific survival</measure>
    <time_frame>two years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Upper Tract Urothelial Carcinoma</condition>
  <condition>Bladder Recurrence</condition>
  <arm_group>
    <arm_group_label>Blank control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>do not use prophylactic intravesical chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single intravesical instillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravesical instillation within 24 hours postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple intravesical instillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pharmorubicin or pirarubicin</intervention_name>
    <description>pharmorubicin 50mg pirarubicin 30mg</description>
    <arm_group_label>single intravesical instillation</arm_group_label>
    <arm_group_label>multiple intravesical instillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who were clinically diagnosed with UTUC

          2. Treated with radical nephroureterectomy

        Exclusion Criteria:

          1. Distant metastasis

          2. Prior history of bladder or synchronous bladder cancer

          3. Administration of neoadjuvant chemotherapy

          4. Presence of severe complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>September 9, 2015</last_update_submitted>
  <last_update_submitted_qc>September 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Xuesong Li</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

